InvestorsHub Logo
Followers 71
Posts 11465
Boards Moderated 0
Alias Born 12/25/2009

Re: None

Thursday, 11/10/2016 7:56:06 AM

Thursday, November 10, 2016 7:56:06 AM

Post# of 1162
Bristol-Myers' Opdivo successful in late-stage gastric cancer study

Nov. 10, 2016 7:52 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

A Phase 3 clinical trial, ONO-4538-12, assessing Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent gastric cancer resistant to standard therapy met its primary endpoint of overall survival (OS). The company says this is the first immuno-oncology agent to show such a benefit in these patients.

Bristol-Myers and development partner Ono Pharmaceutical Co. Ltd. are working with investigators on the future presentation of the results.

Opdivo is currently approved for the treatment of non-small cell lung cancer, melanoma, kidney cancer and classical Hodgkin lymphoma. It is BMY's fastest growing product and is poised to overtake top-selling Eliquis in the near future. Over the past four quarters, Opdivo's sales were $2.929B compared to $2.997B for Eliquis.
_____________________________________________
http://seekingalpha.com/news/3223294-bristol-myers-opdivo-successful-late-stage-gastric-cancer-study

BMY
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News